Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Reviews on Recent Clinical Trials
  4. Volume 20, Issue 1
  5. Article
Volume 20, Issue 1
  • ISSN: 1574-8871
  • E-ISSN: 1876-1038

Abstract

Background

It has been proposed that colchicine may have the potential to prevent cardiovascular and cerebrovascular dysfunctions.

Objective

This study evaluated the impact of colchicine on preventing recurrent stroke in patients with both ischemic stroke (IS) and atrial fibrillation (AF).

Methods

A randomized, double-blinded, placebo-controlled trial was conducted at Golestan Hospital (Ahvaz, Iran) over one year, involving IS patients with AF. Demographic and clinical data were collected from the participants, who were then assigned to either the intervention or placebo groups. The experimental group was administered colchicine at a dosage of 0.05 mg twice daily for one year, while the control group received a placebo at a comparable dosage over the same timeframe.

Results

In one year, 108 patients completed the study. There were 55 patients in the intervention group and 53 patients in the placebo group. During the second trimester of the trial, three patients in the colchicine group and 10 patients in the placebo group experienced recurrent strokes. Gastrointestinal issues were the most commonly reported complications (33 cases) among the two groups, followed by myalgia (8 patients). There were significant differences in the frequency of recurrent stroke and serum levels of C-reactive protein (CRP) between the colchicine and placebo groups ( < 0.05) after intervention.

Conclusion

In this study, colchicine was effective in reducing recurrent stroke and CRP levels in IS patients with AF compared to the control group. Further randomized controlled trials with larger sample sizes and extended durations are recommended to validate the results of this trial.

Clinical Trial Registration Number

IRCT20130311012781N5.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/rrct/10.2174/0115748871325292240904060109
2024-09-19
2025-04-23

  • From This Site

    /content/journals/rrct/10.2174/0115748871325292240904060109
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. MurphyS.J.X. WerringD.J. Stroke: Causes and clinical features.Medicine202048956156610.1016/j.mpmed.2020.06.00232837228
     [Google Scholar]
  2. PhippsM.S. CroninC.A. Management of acute ischemic stroke.BMJ2020368l698310.1136/bmj.l698332054610
     [Google Scholar]
  3. OwolabiM.O. ThriftA.G. MahalA. IshidaM. MartinsS. JohnsonW.D. PandianJ. Abd-AllahF. YariaJ. PhanH.T. RothG. GallS.L. BeareR. PhanT.G. MikulikR. AkinyemiR.O. NorrvingB. BraininM. FeiginV.L. AbantoC. AberaS.F. AddissieA. AdebayoO. AdeleyeA.O. AdilbekovY. AdilbekovaB. AdoukonouT.A. Aguiar de SousaD. AjagbeT. AkhmetzhanovaZ. AkpaluA. Álvarez AhlgrenJ. AmerisoS. AndonovaS. AwoniyiF.E. BakhietM. BarbozaM. BasriH. BathP. BelloO. BereczkiD. BerettaS. BerkowitzA. Bernabé-OrtizA. BernhardtJ. BerzinaG. BisharyanM. BovetP. BudincevicH. CadilhacD. CasoV. ChenC. ChinJ. ChwojnickiK. ConfortoA. CruzV.T. D’AmelioM. DanielyanK. DavisS. DemarinV. DempseyR. DichgansM. DokovaK. DonnanG. ElkindM.S. EndresM. FischerU. GankpéF. Gaye SaavedraA. GilA. GiroudM. GnedovskayaE. HachinskiV. HafdiM. HamadehR. HamzatT.K. HankeyG. HeldnerM. IbrahimE.A. IbrahimN.M. InoueM. JeeS. JengJ-S. KalkondeY. KamenovaS. KaraszewskiB. KellyP. KhanT. KiechlS. KondybayevaA. KõrvJ. KravchenkoM. KrishnamurthiR.V. KrujaJ. LakkhanaloetM. LanghorneP. LavadosP.M. LawZ.K. LawalA. Lazo-PorrasM. LebedynetsD. LeeT-H. LeungT. LiebeskindD.S. LindsayP. López-JaramilloP. LotufoP.A. Machline-CarrionJ. MakanjuolaA. MarkusH.S. Marquez-RomeroJ.M. MedinaM. MedukhanovaS. MehndirattaM.M. MerkinA. MirrakhimovE. MohlS. Moscoso-PorrasM. Müller-StierlinA. MurphyS. MusaK.I. NasreldeinA. NogueiraR.G. NolteC. NoubiapJ.J. Novarro-EscuderoN. OgunY. OguntoyeR.A. OrabyM.I. OsundinaM. OvbiageleB. OrkenD.N. OzdemirA.Ö. OzturkS. PaccotM. PhromjaiJ. PiradovP. PlatzT. PotparaT. RantaA. RathoreF. RichardE. SaccoR.L. SahathevanR. Santos CarquínI. SaposnikG. SarfoF.S. SharmaM. ShethK. ShobhanaA. SuwanwelaN. SvyatoI. SylajaP.N. TaoX. ThakurK.T. ToniD. TopcuogluM.A. ToralesJ. TowfighiA. TruelsenT.C. TsiskaridzeA. Tulloch-ReidM. UsecheN. VanackerP. VassilopoulouS. VukorepaG. VuleticV. WahabK.W. WangW. WijeratneT. WolfeC. YifruY.M. Yock-CorralesA. YonemotoN. YperzeeleL. ZhangP. Stroke Experts Collaboration Group Primary stroke prevention worldwide: Translating evidence into action.Lancet Public Health202271e74e8510.1016/S2468‑2667(21)00230‑934756176
     [Google Scholar]
  4. KatanM. LuftA. Global burden of stroke.Seminars in neurology.Thieme Medical Publishers201810.1055/s‑0038‑1649503
     [Google Scholar]
  5. AlkhalilM. Mechanistic insights to target atherosclerosis residual risk.Curr. Probl. Cardiol.202146310043210.1016/j.cpcardiol.2019.06.00431285037
     [Google Scholar]
  6. ParkJ.H. OvbiageleB. Optimal combination secondary prevention drug treatment and stroke outcomes.Neurology2015841505610.1212/WNL.000000000000109925411440
     [Google Scholar]
  7. RahmanF. KwanG.F. BenjaminE.J. Global epidemiology of atrial fibrillation.Nat. Rev. Cardiol.2014111163965410.1038/nrcardio.2014.11825113750
     [Google Scholar]
  8. MarkidesV. SchillingR.J. Atrial fibrillation: Classification, pathophysiology, mechanisms and drug treatment.Br. Heart J.200389893994310.1136/heart.89.8.93912860883
     [Google Scholar]
  9. EssaH. HillA.M. LipG.Y.H. Atrial fibrillation and stroke.Card. Electrophysiol. Clin.202113124325510.1016/j.ccep.2020.11.00333516402
     [Google Scholar]
  10. StaerkL. ShererJ.A. KoD. BenjaminE.J. HelmR.H. Atrial fibrillation.Circ. Res.201712091501151710.1161/CIRCRESAHA.117.30973228450367
     [Google Scholar]
  11. ChughS.S. HavmoellerR. NarayananK. SinghD. RienstraM. BenjaminE.J. GillumR.F. KimY.H. McAnultyJ.H.Jr ZhengZ.J. ForouzanfarM.H. NaghaviM. MensahG.A. EzzatiM. MurrayC.J.L. Worldwide epidemiology of atrial fibrillation: A global burden of disease 2010 study.Circulation2014129883784710.1161/CIRCULATIONAHA.113.00511924345399
     [Google Scholar]
  12. KishoreA. Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: A systematic review and meta-analysis.Stroke201445252052610.1161/STROKEAHA.113.003433
     [Google Scholar]
  13. WasmerK. EckardtL. BreithardtG. Predisposing factors for atrial fibrillation in the elderly.J. Geriatr. Cardiol.201714317918428592961
     [Google Scholar]
  14. SchnabelR.B. YinX. GonaP. LarsonM.G. BeiserA.S. McManusD.D. Newton-ChehC. LubitzS.A. MagnaniJ.W. EllinorP.T. SeshadriS. WolfP.A. VasanR.S. BenjaminE.J. LevyD. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: A cohort study.Lancet2015386998915416210.1016/S0140‑6736(14)61774‑825960110
     [Google Scholar]
  15. NaserN. DilicM. DurakA. KulicM. PepicE. SmajicE. KusljugicZ. The impact of risk factors and comorbidities on the incidence of atrial fibrillation.Mater. Sociomed.201729423123610.5455/msm.2017.29.231‑23629284990
     [Google Scholar]
  16. GrondM. JaussM. HamannG. StarkE. VeltkampR. NabaviD. HornM. WeimarC. KöhrmannM. WachterR. RosinL. KirchhofP. Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: A prospective multicenter cohort study.Stroke201344123357336410.1161/STROKEAHA.113.00188424130137
     [Google Scholar]
  17. MarchioP. Guerra-OjedaS. VilaJ.M. AldasoroM. VictorV.M. MauricioM.D. Targeting early atherosclerosis: A focus on oxidative stress and inflammation.Oxid. Med. Cell. Longev.20192019113210.1155/2019/856384531354915
     [Google Scholar]
  18. MoriyaJ. Critical roles of inflammation in atherosclerosis.J. Cardiol.2019731222710.1016/j.jjcc.2018.05.01029907363
     [Google Scholar]
  19. BaumgartnerS. BruckertE. GalloA. PlatJ. The position of functional foods and supplements with a serum LDL-C lowering effect in the spectrum ranging from universal to care-related CVD risk management.Atherosclerosis202031111612310.1016/j.atherosclerosis.2020.07.01932861515
     [Google Scholar]
  20. KadoglouN.P.E. ChristodoulouE. KostomitsopoulosN. ValsamiG. The cardiovascular-protective properties of saffron and its potential pharmaceutical applications: A critical appraisal of the literature.Phytother. Res.202135126735675310.1002/ptr.726034448254
     [Google Scholar]
  21. MohammadiS. AsbaghiO. AfrishamR. FarrokhiV. JadidiY. MofidiF. Ashtary-LarkyD. Impacts of supplementation with silymarin on cardiovascular risk factors: A systematic review and dose–response meta-analysis.Antioxidants202413439010.3390/antiox1304039038671838
     [Google Scholar]
  22. NidorfS.M. EikelboomJ.W. BudgeonC.A. ThompsonP.L. Low dose colchicine for secondary prevention of cardiovascular disease.J. Am. Coll. Cardiol.201361440441010.1016/j.jacc.2012.10.02723265346
     [Google Scholar]
  23. TardifJ.C. KouzS. WatersD.D. BertrandO.F. DiazR. MaggioniA.P. PintoF.J. IbrahimR. GamraH. KiwanG.S. BerryC. López-SendónJ. OstadalP. KoenigW. AngoulvantD. GrégoireJ.C. LavoieM.A. DubéM.P. RhaindsD. ProvencherM. BlondeauL. OrfanosA. L’AllierP.L. GuertinM.C. RoubilleF. Efficacy and safety of low dose colchicine after myocardial infarction.N. Engl. J. Med.2019381262497250510.1056/NEJMoa191238831733140
     [Google Scholar]
  24. NidorfS.M. FioletA.T.L. MosterdA. EikelboomJ.W. SchutA. OpstalT.S.J. TheS.H.K. XuX.F. IrelandM.A. LenderinkT. LatchemD. HoogslagP. JerzewskiA. NieropP. WhelanA. HendriksR. SwartH. SchaapJ. KuijperA.F.M. van HessenM.W.J. SaklaniP. TanI. ThompsonA.G. MortonA. JudkinsC. BaxW.A. DirksenM. AlingsM. HankeyG.J. BudgeonC.A. TijssenJ.G.P. CornelJ.H. ThompsonP.L. LoDoCo2 Trial Investigators Colchicine in patients with chronic coronary disease.N. Engl. J. Med.2020383191838184710.1056/NEJMoa202137232865380
     [Google Scholar]
  25. TongD.C. QuinnS. NasisA. HiewC. Roberts-ThomsonP. AdamsH. SriamareswaranR. HtunN.M. WilsonW. StubD. van GaalW. HowesL. CollinsN. YongA. BhindiR. WhitbournR. LeeA. HengelC. AsrressK. FreemanM. AmerenaJ. WilsonA. LaylandJ. Colchicine in patients with acute coronary syndrome: The Australian COPS randomized clinical trial.Circulation2020142201890190010.1161/CIRCULATIONAHA.120.05077132862667
     [Google Scholar]
  26. KoflerT. KurmannR. LehnickD. CioffiG.M. ChandranS. Attinger-TollerA. ToggweilerS. KobzaR. MoccettiF. CuculiF. JollyS.S. BossardM. Colchicine in patients with coronary artery disease: A systematic review and meta-analysis of randomized trials.J. Am. Heart Assoc.20211016e02119810.1161/JAHA.121.02119834369166
     [Google Scholar]
  27. ButtA.K. CaveB. MaturanaM. TowersW.F. KhouzamR.N. The role of colchicine in coronary artery disease.Curr. Probl. Cardiol.202146310069010.1016/j.cpcardiol.2020.10069032994053
     [Google Scholar]
  28. AimoA. Pascual-FigalD.A. BarisonA. CedielG. VicenteÁ.H. SaccaroL.F. EmdinM. Bayes-GenisA. Colchicine for the treatment of coronary artery disease.Trends Cardiovasc. Med.202131849750410.1016/j.tcm.2020.10.00733096241
     [Google Scholar]
  29. KhandkarC. VaidyaK. PatelS. Colchicine for stroke prevention: A systematic review and meta-analysis.Clin Ther201941358259010.1016/j.clinthera.2019.02.003
     [Google Scholar]
  30. ImazioM. NidorfM. Colchicine and the heart.Eur. Heart J.202142282745276010.1093/eurheartj/ehab22133961006
     [Google Scholar]
  31. AdeR. Colchicine, current advances and future prospects.Nusantara Biosci201022
     [Google Scholar]
  32. DasgebB. KornreichD. McGuinnK. OkonL. BrownellI. SackettD.L. Colchicine: An ancient drug with novel applications.Br. J. Dermatol.2018178235035610.1111/bjd.1589628832953
     [Google Scholar]
  33. RidkerP.M. LüscherT.F. Anti-inflammatory therapies for cardiovascular disease.Eur. Heart J.201435271782179110.1093/eurheartj/ehu20324864079
     [Google Scholar]
  34. HemkensL.G. EwaldH. GloyV.L. ArpagausA. OluK.K. NidorfM. GlinzD. NordmannA.J. BrielM. Cardiovascular effects and safety of long-term colchicine treatment: Cochrane review and meta-analysis.Heart2016102859059610.1136/heartjnl‑2015‑30854226830663
     [Google Scholar]
  35. VaidyaK. MartínezG. PatelS. The role of colchicine in acute coronary syndromes.Clin. Ther.2019411112010.1016/j.clinthera.2018.07.02330185392
     [Google Scholar]
  36. HennessyT. SohL. BowmanM. KurupR. SchultzC. PatelS. HillisG.S. The low dose colchicine after myocardial infarction (LoDoCo-MI) study: A pilot randomized placebo controlled trial of colchicine following acute myocardial infarction.Am. Heart J.2019215626910.1016/j.ahj.2019.06.00331284074
     [Google Scholar]
  37. DeftereosS. GiannopoulosG. AngelidisC. AlexopoulosN. FilippatosG. PapoutsidakisN. SianosG. GoudevenosJ. AlexopoulosD. PyrgakisV. ClemanM.W. ManolisA.S. TousoulisD. LekakisJ. Anti-inflammatory treatment with colchicine in acute myocardial infarction: A pilot study.Circulation2015132151395140310.1161/CIRCULATIONAHA.115.01761126265659
     [Google Scholar]
  38. MartínezG.J. CelermajerD.S. PatelS. The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation.Atherosclerosis201826926227110.1016/j.atherosclerosis.2017.12.02729352570
     [Google Scholar]
  39. MartínezG.J. RobertsonS. BarracloughJ. XiaQ. MallatZ. BursillC. CelermajerD.S. PatelS. Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome.J. Am. Heart Assoc.201548e00212810.1161/JAHA.115.00212826304941
     [Google Scholar]
  40. VermaS. EikelboomJ.W. NidorfS.M. Al-OmranM. GuptaN. TeohH. FriedrichJ.O. Colchicine in cardiac disease: A systematic review and meta-analysis of randomized controlled trials.BMC Cardiovasc. Disord.20151519610.1186/s12872‑015‑0068‑326318871
     [Google Scholar]
  41. PapageorgiouN. BriasoulisA. LazarosG. ImazioM. TousoulisD. Colchicine for prevention and treatment of cardiac diseases: A meta-analysis.Cardiovasc. Ther.2017351101810.1111/1755‑5922.1222627580061
     [Google Scholar]
  42. CondelloF. Association between colchicine treatment and clinical outcomes in patients with coronary artery disease: Systematic review and meta-analysis.European Cardiology Review202116
     [Google Scholar]
  43. AlkhalilM. Al-AttaA. KuzemczakM. Colchicine for the prevention of ischemic stroke: An updated meta-analysis of randomized clinical trials.Brain Circ.20217318719310.4103/bc.bc_24_2134667902
     [Google Scholar]
  44. KellyP.J. MurphyS. CoveneyS. PurroyF. LemmensR. TsivgoulisG. PriceC. Anti-inflammatory approaches to ischaemic stroke prevention.J. Neurol. Neurosurg. Psychiatry201889221121810.1136/jnnp‑2016‑31481728935831
     [Google Scholar]
  45. ChoiS.E. SagrisD. HillA. LipG.Y.H. Abdul-RahimA.H. Atrial fibrillation and stroke.Expert Rev. Cardiovasc. Ther.2023211355610.1080/14779072.2023.216031936537565
     [Google Scholar]
  46. Escudero-MartínezI. Morales-CabaL. SeguraT. Atrial fibrillation and stroke: A review and new insights.Trends Cardiovasc. Med.2023331232910.1016/j.tcm.2021.12.00134890796
     [Google Scholar]
  47. HuY.F. ChenY.J. LinY.J. ChenS.A. Inflammation and the pathogenesis of atrial fibrillation.Nat. Rev. Cardiol.201512423024310.1038/nrcardio.2015.225622848
     [Google Scholar]
  48. ZhouX. DudleyS.C.Jr Evidence for inflammation as a driver of atrial fibrillation.Front. Cardiovasc. Med.202076210.3389/fcvm.2020.0006232411723
     [Google Scholar]
  49. HaradaM. Van WagonerD.R. NattelS. Role of inflammation in atrial fibrillation pathophysiology and management.Circ. J.201579349550210.1253/circj.CJ‑15‑013825746525
     [Google Scholar]
  50. NidorfM. ThompsonP.L. Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease.Am. J. Cardiol.200799680580710.1016/j.amjcard.2006.10.03917350370
     [Google Scholar]
  51. KatsanosA.H. PalaiodimouL. PriceC. ThemistocleousM. LemmensR. MichopoulosI. GeorgakisM.K. WeimarC. KellyP. TsivgoulisG. An updated meta-analysis of RCTs of colchicine for stroke prevention in patients with coronary artery disease.J. Clin. Med.20211014311010.3390/jcm1014311034300276
     [Google Scholar]
  52. LiJ. Colchicine in patients with acute ischaemic stroke or transient ischaemic attack (CHANCE-3): Multicentre, double blind, randomised, placebo controlled trial.BMJ2024385
     [Google Scholar]
  53. KongP. CuiZ.Y. HuangX.F. ZhangD.D. GuoR.J. HanM. Inflammation and atherosclerosis: signaling pathways and therapeutic intervention.Signal Transduct. Target. Ther.20227113110.1038/s41392‑022‑00955‑735459215
     [Google Scholar]
  54. TousoulisD. KampoliA.M. PapageorgiouN. AndroulakisE. AntoniadesC. ToutouzasK. StefanadisC. Pathophysiology of atherosclerosis: The role of inflammation.Curr. Pharm. Des.201117374089411010.2174/13816121179876484322204371
     [Google Scholar]
  55. TuttolomondoA. Di RaimondoD. PecoraroR. ArnaoV. PintoA. LicataG. Atherosclerosis as an inflammatory disease.Curr. Pharm. Des.201218284266428810.2174/13816121280248123722390643
     [Google Scholar]
  56. WongB.W. MeredithA. LinD. McManusB.M. The biological role of inflammation in atherosclerosis.Can. J. Cardiol.201228663164110.1016/j.cjca.2012.06.02322985787
     [Google Scholar]
  57. YuanB. MengX. WangA. NiuS. XieX. JingJ. LiH. ChangL. WangY. LiJ. Effect of different doses of colchicine on high sensitivity C-reactive protein in patients with acute minor stroke or transient ischemic attack: A pilot randomized controlled trial.Eur. J. Pharm. Sci.202217810628810.1016/j.ejps.2022.10628836041708
     [Google Scholar]
  58. LiJ. PanY. WangM. MengX. LinJ. LiZ. LiH. WangY. ZhaoX. LiuL. WangY. Predictive role of hsCRP in recurrent stroke differed according to severity of cerebrovascular disease: Analysis from a prospective cohort study.J. Clin. Med.2023124167610.3390/jcm1204167636836211
     [Google Scholar]
  59. JohnstonS.C. AmarencoP. DenisonH. EvansS.R. HimmelmannA. JamesS. KnutssonM. LadenvallP. MolinaC.A. WangY. THALES Investigators Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA.N. Engl. J. Med.2020383320721710.1056/NEJMoa191687032668111
     [Google Scholar]
  60. LiJ. PanY. XuJ. LiS. WangM. QuanK. MengX. LiH. LinJ. WangY. ZhaoX. LiuL. WangY. CNSR-III Investigators Residual inflammatory risk predicts poor prognosis in acute ischemic stroke or transient ischemic attack patients.Stroke20215292827283610.1161/STROKEAHA.120.03315234281380
     [Google Scholar]
  61. O’DonoghueM.L. BraunwaldE. WhiteH.D. SteenD.P. LukasM.A. TarkaE. StegP.G. HochmanJ.S. BodeC. MaggioniA.P. ImK.A. ShannonJ.B. DaviesR.Y. MurphyS.A. CrugnaleS.E. WiviottS.D. BonacaM.P. WatsonD.F. WeaverW.D. SerruysP.W. CannonC.P. SOLID-TIMI 52 Investigators Effect of darapladib on major coronary events after an acute coronary syndrome: The SOLID-TIMI 52 randomized clinical trial.JAMA2014312101006101510.1001/jama.2014.1106125173516
     [Google Scholar]
  62. O’DonoghueM.L. GlaserR. CavenderM.A. AylwardP.E. BonacaM.P. BudajA. DaviesR.Y. DellborgM. FoxK.A.A. GutierrezJ.A.T. HammC. KissR.G. KovarF. KuderJ.F. ImK.A. LeporeJ.J. Lopez-SendonJ.L. OphuisT.O. ParkhomenkoA. ShannonJ.B. SpinarJ. TanguayJ.F. RudaM. StegP.G. TherouxP. WiviottS.D. LawsI. SabatineM.S. MorrowD.A. LATITUDE-TIMI 60 Investigators Effect of losmapimod on cardiovascular outcomes in patients hospitalized with acute myocardial infarction: A randomized clinical trial.JAMA2016315151591159910.1001/jama.2016.360927043082
     [Google Scholar]
  63. KellyP. LemmensR. WeimarC. WalshC. PurroyF. BarberM. CollinsR. CroninS. CzlonkowskaA. DesfontainesP. De PauwA. EvansN.R. FischerU. FonsecaC. ForbesJ. HillM.D. JatuzisD. KõrvJ. KraftP. KruuseC. LynchC. McCabeD. MikulikR. MurphyS. NederkoornP. O’DonnellM. SandercockP. SchroederB. ShimG. TobinK. WilliamsD.J. PriceC. Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): A randomised controlled trial.Lancet20244041044812513310.1016/S0140‑6736(24)00968‑138857611
     [Google Scholar]
  64. GohC.X.Y. TanY.K. TanC.H. LeowA.S.T. HoJ.S.Y. TanN.H.W. GohS. HoA.F.W. SharmaV.K. ChanB.P.L. YeoL.L.L. TanB.Y.Q. The use of colchicine as an anti-inflammatory agent for stroke prevention in patients with coronary artery disease: A systematic review and meta-analysis.J. Thromb. Thrombolysis202254118319010.1007/s11239‑022‑02659‑935538274
     [Google Scholar]
  65. SarzaeemM. Low dose Colchicine in prevention of atrial fibrillation after coronary artery bypass graft: A double blind clinical trial.Tehran Univ. Med. J.2014723
     [Google Scholar]
  66. TsivgoulisG. KatsanosA.H. GiannopoulosG. PanagopoulouV. JatuzisD. LemmensR. DeftereosS. KellyP.J. The role of colchicine in the prevention of cerebrovascular ischemia.Curr. Pharm. Des.201824666867410.2174/138161282466618011610031029336246
     [Google Scholar]
  67. LennerzC. BarmanM. TantawyM. SopherM. WhittakerP. Colchicine for primary prevention of atrial fibrillation after open heart surgery: Systematic review and meta-analysis.Int. J. Cardiol.201724912713710.1016/j.ijcard.2017.08.03928918897
     [Google Scholar]
  68. LiuC.H. LinY.S. SungP.S. WeiY.C. ChangT.Y. LeeT.H. LeeC.Y. LiY.R. Colchicine use and risks of stroke recurrence in acute non-cardiogenic ischemic stroke patients: A population-based cohort study.J. Pers. Med.202111993510.3390/jpm1109093534575712
     [Google Scholar]
  69. MassonW. LoboM. MolineroG. MassonG. Lavalle-CoboA. Role of colchicine in stroke prevention: An updated meta-analysis.J. Stroke Cerebrovasc. Dis.202029510475610.1016/j.jstrokecerebrovasdis.2020.10475632160956
     [Google Scholar]
  70. SamuelM. TardifJ.C. BouabdallaouiN. KhairyP. DubéM.P. BlondeauL. GuertinM.C. Colchicine for secondary prevention of cardiovascular disease: A systematic review and meta-analysis of randomized controlled trials.Can. J. Cardiol.202137577678510.1016/j.cjca.2020.10.00633075455
     [Google Scholar]
  71. FioletA.T.L. OpstalT.S.J. MosterdA. EikelboomJ.W. JollyS.S. KeechA.C. KellyP. TongD.C. LaylandJ. NidorfS.M. ThompsonP.L. BudgeonC. TijssenJ.G.P. CornelJ.H. Efficacy and safety of low-dose colchicine in patients with coronary disease: A systematic review and meta-analysis of randomized trials.Eur. Heart J.202142282765277510.1093/eurheartj/ehab11533769515
     [Google Scholar]
  72. SiniscalchiA. LochnerP. De SarroG. GallelliL. Is colchicine involved in managing stroke?Curr. Vasc. Pharmacol.202321314514610.2174/157016112166623051914371637211843
     [Google Scholar]
  73. SlobodnickA. ShahB. KrasnokutskyS. PillingerM.H. Update on colchicine, 2017.Rheumatology201857Suppl. 1i4i1110.1093/rheumatology/kex45329272515
     [Google Scholar]
  74. NidorfS.M. Ben-ChetritE. RidkerP.M. Low-dose colchicine for atherosclerosis: Long-term safety.Eur. Heart J.202445181596160110.1093/eurheartj/ehae20838596868
     [Google Scholar]
  75. DeftereosS. GiannopoulosG. KossyvakisC. EfremidisM. PanagopoulouV. KaoukisA. RaisakisK. BourasG. AngelidisC. TheodorakisA. DrivaM. DoudoumisK. PyrgakisV. StefanadisC. Colchicine for prevention of early atrial fibrillation recurrence after pulmonary vein isolation: A randomized controlled study.J. Am. Coll. Cardiol.201260181790179610.1016/j.jacc.2012.07.03123040570
     [Google Scholar]
/content/journals/rrct/10.2174/0115748871325292240904060109
Loading
Effect of Colchicine for Prevention of Recurrent Stroke in Ischemic Stroke Patients with Atrial Fibrillation: A Randomized Double-blinded Placebo-controlled Trial
Rev. Recent Clin. Trials 20, 59 (2025); https://doi.org/10.2174/0115748871325292240904060109
/content/journals/rrct/10.2174/0115748871325292240904060109
/content/journals/rrct/10.2174/0115748871325292240904060109
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): atrial fibrillation; cerebrovascular dysfunctions; colchicine; CRP; Ischemic stroke; therapeutic options

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test